Redeye will cease its coverage of 2cureX, effective 1st March 2023.
Redeye comments on 2cureX’s Q4’22 report. The company summarizes the past year and highlights its strong enrollment for the IGNITE program.
Redeye is encouraged to learn that 2cureX has signed IndiTreat® distribution agreements for Switzerland and Austria with pedoc Medic, as wel...
Redeye comments on 2cureX’s Q3’22 report. The company highlights positive results from an independent survey investigating the need for new ...
Representatives from 2cureX's management talk about the company and its strategy for the coming years.
Redeye comments on 2cureX’s Q2’22 report. Operational activities are progressing well, laying the fundaments for a commercial roll-out Howev...
Redeye is encouraged to learn that 2cureX has signed its 10th distribution agreement.
Redeye believes getting closer to the customers in the company’s home markets is key to a stronger and more efficient rollout and uptake of...
Redeye comments on 2cureX’s Q1’22 report, which did not include any big surprises.
Med distributörer och utvalda sjukhus i Europa ska 2cureX bygga en marknad för bättre cancerbehandling.
Redeye endorses 2cureX launching its third test, IndiTreat Explore, and thereby completing its portfolio rollout plan for 2022.
Redeye comments on 2cureX’s Q4’21 report. It has been an eventful quarter for 2cureX, including the launch of its new test for patients with...
(Tillägg: länk till analysen) Mangold uppdaterar 2cureX, som utvecklat IndiTreat för bättre cancerbehanling, inför den stundande lanseringen...
Mangold uppdaterar 2cureX, som utvecklat IndiTreat för bättre cancerbehanling, inför den stundande lanseringen i Europa.
Redeye comments on 2cureX’s Q2 2021 report, with the company continually taking required steps toward IndiTreat commercialization.
Redeye endorses 2cureX getting ISO 13485:2016 certified, signifying a critical milestone towards compliance with EU Regulation 2017/746.
